Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 756-759

  Venkatramani, Rajkumar ^a,b   Malogolowkin, Marcio H ^c   Mascarenhas, Leo ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Bevacizumab; Chemotherapy; Irinotecan; Relapse; Temozolomide; Vincristine; Wilms tumor

Indexed keywords

ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE; VINCRISTINE;

ADOLESCENT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD TOXICITY; BODY WEIGHT DISORDER; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CHILD; DIARRHEA; EPISTAXIS; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; HYPERTENSION; LUNG NODULE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROBLASTOMA; NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

BEVACIZUMAB; CHEMOTHERAPY; IRINOTECAN; RELAPSE; TEMOZOLOMIDE; VINCRISTINE; WILMS TUMOR;

ADOLESCENT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; DACARBAZINE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; VINCRISTINE; WILMS TUMOR;

EID: 84893463503     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24785     Document Type: Article

References (20)

1. Reinhard H, Schmidt A, Furtwängler R, et al. Outcome of relapses of nephroblastoma in patients registered in the SIOP/GPOH trials and studies. Oncol Rep 2008; 20:463-467.
2. Malogolowkin M, Cotton CA, Green DM, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine, actinomycin D, and doxorubicin. A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2008; 50:236-241.
3. Green DM, Cotton CA, Malogolowkin M, et al. Treatment of Wilms tumor relapsing after initial treatment with vincristine and actinomycin D: A report from the National Wilms Tumor Study Group. Pediatr Blood Cancer 2007; 48:493-499.
4. Grundy P, Breslow N, Green DM, et al. Prognostic factors for children with recurrent Wilms' tumor: Results from the Second and Third National Wilms' Tumor Study. J Clin Oncol 1989; 7:638-647.
5. Venkatramani R, Malogolowkin M, Davidson TB, et al. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors. PLoS ONE 2013; 8:e68416.
6. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A Pediatric Oncology Group Study. Clin Cancer Res 2001; 7:32-37.
7. Vassal G, Doz F, Frappaz D, et al. A phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J Clin Oncol 2003; 21:3844-3852.
8. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004; 10:840-848.
9. Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 2008; 26:399-405.
10. Benesch M, Windelberg M, Sauseng W, et al. Compassionate use of bevacizumab (Avastin®) in children and young adults with refractory or recurrent solid tumors. Ann Oncol 2008; 19:807-813.
11. Metzger ML, Stewart CF, Freeman BB III, et al. Topotecan is active against Wilms' tumor: Results of a multi-institutional phase II study. J Clin Oncol 2007; 25:3130-3136.
12. Houghton PJ, Stewart CF, Cheshire PJ, et al. Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin Cancer Res 2000; 6:4110-4118.
13. Rowe DH, Huang J, Kayton ML, et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000; 35:30-32.
14. Frischer JS, Huang J, Serur A, et al. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int J Oncol 2004; 25:549-553.
15. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
16. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26:2013-2019.
17. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 54:538-545.
18. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
19. Pein F, Michon J, Valteau-Couanet D, et al. High-dose melphalan, etoposide, and carboplatin followed by autologous stem-cell rescue in pediatric high-risk recurrent Wilms' tumor: A French Society of Pediatric Oncology study. J Clin Oncol 1998; 16:3295-3301.
20. Ha TC, Spreafico F, Graf N, et al. An international strategy to determine the role of high dose therapy in recurrent Wilms' tumour. Eur J Cancer 2012; 49:194-210.